It predicts that the Act will result in a new wave of adverse medical inflation and cost increases. This is particularly worrying given that sharp increases in delivery costs in recent years have added further pressure to schemes' operating environment. Inevitably some schemes will also fall by the wayside. In view of the difficult operating environment experienced by schemes over the past two years and the adverse impact of the new Act, DCR has lowered the medical schemes industry risk ceiling to AA- from AA previously, with many schemes' ratings falling by one or even two notches. But the last word goes to Gore whose one wish for the industry is that it become more positive.
Nobody can argue with that.